1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
Articles > Article · 2022
Authors: L. Albiges, H.P. Gurney, V. Atduev, C. Suárez, M.A. Climent Duran, D. Pook, P. Tomczak, P. Barthelemy, J-L. Lee, T. Nalbandian, V. Stus, T. Ferguson, P. Wiechno, E. Gokmen, L. Lacombe, C. Gedye, R. Perini, M. Sharma, C. Li, C-H. Lee
Annals of Oncology, International, WoS, 2022, vol 33, pp S1204-S1205